Damian Garde
STAT
Somerville, MA, United States
Contact Damian
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Damian:
SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now biotech startups are left wondering: Who’s going to finance the industry? → Read More
BridgeBio’s treatment for genetic cause of dwarfism accelerates growth in small study
A novel drug for the most common cause of dwarfism accelerated children’s growth in a small but closely watched clinical trial, the company BridgeBio said. → Read More
Heart repair, risky genes, and AI: the buzz from a giant cardiovascular conference
An implantable heart clip from Abbott Laboratories led to reductions in hospitalization and death compared to standard care in a study enrolling severely ill patients, an endorsement of a device whose benefits have long been divisive. → Read More
Listen: The next CRISPR fight, cheaper insulin, & an FDA shuffle
Who invented CRISPR 2.0? What happens when a drug company actually lowers prices? And is Novavax going to survive? STAT's podcast covers all that and more. → Read More
Pharmalittle: India sends two pharma execs to prison; FDA's neurology boss departs
Billy Dunn, the high-ranking FDA official behind the polarizing approval of Aduhelm, is leaving the agency. → Read More
FDA's Billy Dunn to leave the agency
Billy Dunn, who presided over the polarizing approval of the Alzheimer’s disease treatment Aduhelm, is leaving the FDA after more than 15 years at the agency. → Read More
Listen: Vertex vs. insurers, Moderna's future, & biotech's long winter
What makes a drug quintuple in cost? How do you follow inventing a Covid-19 vaccine? And what did we learn from biotech's unicorn era? Find out on the latest episode of "The Readout LOUD." → Read More
Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more
Vas Narasimhan has been CEO of Novartis since 2018. He talked with STAT about the industry's struggles in Washington, the future of Novartis, and whether the biotech sector is still a little overvalued. → Read More
Listen: Vas Narasimhan on the future of pharma, plus Moderna’s vaccine promise & a biotech presidential bid
Is the pharmaceutical lobby on the ropes? What does it mean when a vaccine is "free"? And does biotech prepare you for the presidency? All that and more on the new episode of "The Readout LOUD." → Read More
The return of bird flu and the effects of pandemic fatigue
Just how alarming is bird flu? And did we learn enough from Covid-19 to be sensible about it? All that and more on the new episode of "The Readout LOUD" podcast. → Read More
Bayer, facing investor ire, appoints an outsider CEO
Bayer named former Roche executive Bill Anderson as its new CEO, a decision that follows escalating pressure from shareholders. → Read More
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
Is the next Lipitor on the way? When is a pandemic over-over? And what's a Texas two-step? All that and more on the new episode of "The Readout LOUD" #podcast. → Read More
Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score
Where do new drugs come from? Does science need billionaires? And do normal people care about messenger RNA? Find out on the latest episode of "The Readout LOUD" #podcast. → Read More
Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants
What does 2023 have in store for biotech? How can the FDA win back trust? And who came up with "XBB.1.5"? Find out on this week's episode of "The Readout LOUD" #podcast. → Read More
In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer's treatments
Crucial questions remain for the Food and Drug Administration, Biogen, and the future of treating Alzheimer’s disease. → Read More
FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
Here are eight key takeaways from the congressional investigation of the FDA's approval of the Biogen Alzheimer's drug Aduhelm. → Read More
Get ready for 'the electric vehicles of biopharma': Three biotech trends to watch in 2023
Looking ahead to a promising Alzheimer's treatment, creative deal-making techniques, and a new generation of metabolic drugs. → Read More
2022 in review, CEO indictments, & the year ahead
When does optimism become criminal? Why can't biotech find its way back? And what's going to happen in 2023? All that and more on "The Readout LOUD" this week. → Read More
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
The latest Alzheimer’s disease treatment from Eisai and Biogen needs to be cheaper than $20,000 a year to be cost-effective, according to a draft analysis from an influential nonprofit organization. → Read More
Listen: Leaky health data, ASH22, & what it takes to get booed by your peers
Why do billionaires get booed? How does Facebook end up with sensitive health data? And does biotech have a dribbling problem? All that and more on the latest episode of "The Readout LOUD" #podcast. → Read More